Palbociclib, sold under the brand name Ibrance among others, is a targeted therapy medication developed by Pfizer for the treatment of hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer. It is commonly prescribed for advanced or metastatic breast cancer in combination with endocrine therapy, such as letrozole or fulvestrant.
Palbociclib is part of a class of drugs called cyclin-dependent kinase (CDK) inhibitors. It works by targeting specific proteins involved in cell division, slowing or halting the progression of cancer. Palbociclib is administered orally as a capsule, taken once daily in cycles.
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
![2-Bromo-3-[2-chloro-4-(cyclopentylamino)-5-pyrimidinyl]-2-butenoic Acid](https://veeprho.com/wp-content/uploads/2025/06/VE0024349-2-Bromo-3-2-chloro-4-cyclopentylamino-5-pyrimidinyl-2-butenoic-Acid.png "2-Bromo-3-[2-chloro-4-(cyclopentylamino)-5-pyrimidinyl]-2-butenoic Acid")
Parent: Palbociclib
Parent: Palbociclib / Amenamevir
Parent: Palbociclib
Parent: Palbociclib
![6-Acetyl-2-amino-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one](https://veeprho.com/wp-content/uploads/2024/10/VE0022033-6-Acetyl-2-amino-8-cyclopentyl-5-methyl-8H-pyrido-2-3-d-pyrimidin-7-one.png "6-Acetyl-2-amino-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one")
Parent: Palbociclib
![6-Acetyl-8-cyclopentyl-2-hydroxy-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one](https://veeprho.com/wp-content/uploads/2022/07/6-Acetyl-8-cyclopentyl-2-hydroxy-5-methylpyrido5B2-3-d5Dpyrimidin-78H-one.png "6-Acetyl-8-cyclopentyl-2-hydroxy-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one")
Parent: Palbociclib
Parent: Palbociclib
Parent: Palbociclib
Like all pharmaceuticals, palbociclib may develop impurities during manufacturing and storage. Regulatory agencies like the U.S. FDA and EMA ensure strict control over these impurities to maintain the medication’s safety, efficacy, and quality.
Types of Impurities in Palbociclib
Related Substances
These are chemically related compounds or byproducts formed during the synthesis of palbociclib. Controlling related substances ensures the medication’s purity and therapeutic effectiveness.
Degradation Products
Palbociclib can degrade over time when exposed to environmental factors such as heat, light, or humidity. Proper storage conditions are required to prevent the formation of degradation products that could compromise the drug’s potency and stability.
Residual Solvents
Trace amounts of solvents used during manufacturing may remain in the final product. Regulatory standards ensure these solvents are within safe limits to minimize potential risks to patients.
Analytical Techniques for Monitoring Impurities
Techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (LC-MS) are used to detect and quantify impurities, ensuring palbociclib meets stringent quality and safety requirements.
No, palbociclib is not traditional chemotherapy. It is a targeted therapy classified as a cyclin-dependent kinase (CDK) inhibitor. Unlike chemotherapy, which attacks rapidly dividing cells indiscriminately, palbociclib specifically targets cancer cell growth by inhibiting proteins involved in cell division.
Palbociclib is used for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. It is typically prescribed in combination with endocrine therapy, such as letrozole for postmenopausal women or fulvestrant for individuals whose cancer has progressed after endocrine therapy.
Yes, palbociclib is a CDK inhibitor. It specifically targets cyclin-dependent kinases 4 and 6 (CDK4/6), which are proteins that regulate the cell cycle. By inhibiting these kinases, palbociclib slows the proliferation of cancer cells.
Palbociclib works by selectively inhibiting CDK4 and CDK6, proteins that promote the transition of cells from the G1 to the S phase of the cell cycle. This inhibition prevents cancer cells from dividing and proliferating, effectively slowing tumor growth. When combined with endocrine therapy, palbociclib enhances the treatment’s effectiveness by targeting multiple pathways involved in cancer progression.
